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Abstract
Background: Medication decision-making poses a challenge for a significant proportion of patients. This is an even
more challenging for patients who have complex, rare, immune conditions that affect them at a young age and are
associated with the use of life-long treatment, perceived by some as having significant risk of side effects and toxicity.
Introduction: The aim of our study was to examine the perspectives of women with lupus nephritis on facilitators to
medication decision-making.
Methods: We used the nominal group technique (NGT), a structured formative process to elicit patient perspectives.
An NGT expert moderated eight patient group meetings. Participants (n = 52) responded to the question “What sorts
of things make it easier for people to decide to take the medicines that doctors prescribe
for treating their lupus kidney disease?” Patients nominated, discussed, and prioritized facilitators to medication
decisional processes.
Results: Fifty-two women with lupus nephritis participated in eight NGT meetings (27 African-American, 13 Hispanic,
and 12 Caucasian). Average age was 40.6 years (standard deviation (SD) = 13.3), and disease duration was 11.8 years
(SD = 8.3); 36.5 % obtained at least a college education, and 55.8 % had difficulty in reading health materials. Patients
generated 280 decision-making facilitators (range of 26 to 42 per panel). Of these, 102 (36 %) facilitators were perceived
by patients as having relatively more influence in decision-making processes than others. Prioritized facilitators included
effective patient-physician communication regarding benefits/harms, patient desire to live a normal life and improve
quality of life, concern for their dependents, experiencing benefits and few/infrequent/no harms with lupus
medications, and their affordability. Relative to African-Americans, Caucasian and Hispanic patients endorsed a smaller
percentage of facilitators as influential. Level of agreement with which patients within panels independently agreed in
their selections of the three most influential facilitators ranged from 33 % to 60 %.
Conclusions: We identified facilitators to lupus medication decision-making. This information will be used to populate
a decision aid for lupus nephritis.
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Background
Lupus nephritis, if not treated promptly with appropriate
medications, is a common manifestation of lupus that can
lead to end-stage renal disease and dialysis [1]. Many
patients with lupus do not take their medications regularly
[2]. Although the precise reasons for this are not known,
qualitative research has focused mainly on disease experi-
ence [3–8] or long-term need for these medications [9]
and only in some cases on barriers to medication intake
[9–12] as important contributors to this difficult clinical
problem. A systematic review of studies focused on lupus
medications identified treatment adherence as one of the
five main themes in the management of patients with
lupus [13]. In particular, effective communication by clini-
cians promoted a sense of trust and respect among
patients with lupus, and “medication adherence was their
way of demonstrating their appreciation”.
On the other hand, it is not known what factors help
patients in making a decision to start taking their lupus
medications. This is a large gap in the literature. Medica-
tion decision-making poses a challenge for a significant
proportion of patients [14]. Therefore, we undertook the
current study. Unlike investigators in previous qualita-
tive work in the area of medication adherence, we used
the nominal group technique (NGT) as a more struc-
tured approach to elicit both qualitative (ideas) and
quantitative (ranking) data from patients [15]. Our ob-
jective was to identify a comprehensive array of patient-
reported facilitators and the relative benefit each was
perceived to have in the medication decision-making
process for women with lupus nephritis. We over-
sampled racial/ethnic minorities in our study, given that
the severity of lupus symptoms is higher and outcomes
are worse for minorities with lupus [16, 17]. Our re-
search was guided by a single question aimed at identify-
ing factors that facilitated decisional processes involving
medications for treating lupus nephritis: “What sorts of
things make it easier for people to decide to take the




We recruited patients from the lupus clinics at the
University of Alabama at Birmingham (UAB) and the
University of California at San Francisco (UCSF). All pa-
tients met American College of Rheumatology classifica-
tion criteria for systemic lupus erythematosus and had a
clinical diagnosis of lupus nephritis (based on renal biopsy
or laboratory tests or both).
We convened eight NGT meetings including lupus
nephritis patients who had received treatment and were
following at UAB or UCSF lupus clinics. An expert NGT
researcher (RS) conducted and moderated all NGT
meetings in English between February and April 2014.
The institutional review boards at UAB and UCSF
approved this study. All patients provided written in-
formed consent.
Nominal group technique
The NGT meeting is a facilitated data collection ac-
tivity structured to promote even and equal subject
participation by minimizing the loss of information.
Evidence shows that the NGT, when used correctly,
elicits a greater volume of novel and higher-quality
responses in response to a carefully articulated ques-
tion than the less structured group data collection
approaches such as focus groups and brainstorming
[18, 19]. Moreover, by using the verbatim responses
that are concisely documented on a flip chart as partici-
pants present them to the group, the NGT eliminates a
potential source of investigator-induced interpretive bias
resulting from transcribing and coding audio or video
recordings.
The purpose of NGT meetings was to tap into pa-
tients’ unique insights, knowledge, and lived experiences
to identify different factors that facilitated their decision-
making process involving prescribed lupus medications.
The NGT leader (RS) along with a team member (HQ)
started the sessions with a brief explanation of the pur-
pose and the NGT process. Patients then worked inde-
pendently for about five minutes to develop their own
lists of brief statements/phrases in response to the NGT
question.
Patients were encouraged to think broadly about
the types of things that enhanced the likelihood of
deciding to take the medications prescribed for their
condition. This ensured that each panel generated a
wide array of responses. After five minutes of working
on their own, patients were invited to present their
responses to the group. To promote open disclosure,
increase response volume, and ensure that all patients
had an equal opportunity to present responses, we
used a “round-robin” participation format. This for-
mat involved having each patient, in turn, articulate a
single response without providing any rationale, justi-
fication, or explanation for their response and without
discussion or debate from other members in the
group. All responses were immediately recorded ver-
batim on a flip chart to help participants recollect
previously nominated responses. We continued until
no further responses could be generated. All re-
sponses were then discussed in a non-evaluative fash-
ion to ensure that they were understood from a
common perspective and potentially to obtain add-
itional insights [15].
Patients were asked to silently review the full list of re-
sponses generated during the meeting and to independently
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select three facilitators that they perceived as the most in-
fluential in their decision-making regarding lupus nephritis
medication. Patients recorded their selected responses on
index cards and prioritized the influence each of their selec-
tions from 1 (least influential) to 3 (most influential). The
votes reflecting these priorities were tabulated across pa-
tients in each NGT panel to determine the perceived rela-
tive influence of medication decision-making facilitators
and the level of agreement among patients regarding these
perceptions.
A brief questionnaire was administered at the conclu-
sion of each NGT meeting to obtain basic demographic
data, education level, disease duration and whether the
patient needed assistance in reading materials. Data
from this questionnaire were analyzed at the group level
and not linked with individual responses generated dur-
ing the NGT meetings.
Results
Fifty-two patients with lupus nephritis participated in
eight NGT meetings. Mean age was 40.6 years (standard
deviation (SD) = 13.3), and average disease duration was
11.8 years (SD = 8.3); 36.5 % had obtained at least a col-
lege degree, and 55.8 % indicated a need for some help
(from a family member, friend, and hospital or clinic
staff ) in reading health materials (Table 1). Twenty-
seven were African-American (four nominal groups), 13
were Hispanic (two nominal groups), and 12 were Cau-
casian (two nominal groups).
Patients generated 280 decision-making facilitators (range
from 26 to 42 facilitators per panel) (Table 2). Of these, 102
(36 %) facilitators were perceived by patients as having
relatively more influence in their own decision-making pro-
cesses (i.e., were responses selected from each panel’s gen-
erated list of responses and then assigned weighted votes)
than responses reflecting other facilitators. Differences in
the number of prioritized responses as a percentage of total
generated responses were observed across the panels (range
from 31 % to 52 %).
Relative to African-American patients, Caucasian and
Hispanic patients tended to endorse a smaller percent-
age of facilitators as influential (African-American range
from 41 %–54 % versus Caucasian 32 %–35 % and
Hispanic 35 %–38 %). Rescaled values expressing the
level of agreement or consistency with which patients
within panels independently agreed in their selections of
the three most influential decision-making facilitators
ranged from 33 % for African-American panels (panels 3
and 4) and Hispanic panel 1 to 60 % for Caucasian panel
1 (Table 2).
We attempted to summarize results across the eight
NGTs by race/ethnicity, but the prioritized responses
were too different to allow this grouping. Therefore, fa-
cilitators are presented for each nominal group in the
section below.
NGT group results
The first NGT meeting was conducted at the UAB site
and involved nine African-American women patients
who were between 27 and 66 years of age (mean = 36.9
and SD = 13.15). Most of the patients in this group (7
out of 9) reported their education level as less than a
college degree. Patients in this group generated 31 re-
sponses reflecting potential facilitators of the medication
decision-making process. As indicated by their inde-
pendent assignment of votes (Fig. 1a; see Additional file
1 for more details), the patients who participated in this
meeting collectively endorsed 16 facilitators as relatively
more influential than others with respect to their own
decision-making. The relative influence of each selected
facilitator was then assessed in consideration of both the
number of patients who endorsed it as “personally





Education Need help in reading health materials Disease activity in
past 3 monthsaBelow college College or above No Yes
Mean (SD) Mean (SD) N (%) N (%) N (%) N (%) Mean (SD)
AA1 (9) 36.9 (13.1) 26.4 (12.4) 7 (77.8) 2 (22.2) 5 (55.6) 4 (44.6) 6.1 (2.7)
AA2 (7) 49.1 (4.8) 36.4 (6.3) 6 (85.7) 1 (14.3) 4 (57.1) 3 (42.9) 4.7 (2.8)
AA3 (7) 38.1 (11.9) 28.9 (14.0) 3 (42.9) 4 (57.1) 4 (57.1) 3 (42.9) 5.0 (2.9)
AA4 (4) 42.5 (14.9) 36.1 (18.1) 2 (50.0) 2 (50.0) 1 (25.0) 3 (75.0) 7.3 (3.0)
CA1 (6) 47.3 (19.9) 32.8 (19.3) 5 (83.3) 1 (16.7) 5 (83.3) 1 (16.7) 5.0 (3.2)
CA2 (6) 45.7 (11.5) 32.4 (14.2) 2 (33.3) 4 (66.7) 1 (16.7) 5 (83.3) 3.3 (2.9)
HA1 (6) 31.7 (12.2) 21.2 (4.3) 5 (83.3) 1 (16.7) 5 (83.3) 1 (16.7) 4.0 (2.4)
HA2 (7) 35.4 (12.0) 18.3 (9.3) 4 (57.1) 3 (42.9) 4 (57.1) 3 (42.9) 4.0 (3.6)
Total (52) 40.6 (13.3) 28.5 (13.3) 34 (65.4) 18 (35.6) 29 (55.8) 23 (44.2) 4.9 (2.9)
NGT nominal group technique, N number, SD standard deviation, AA African American, CA Caucasian American, HA Hispanic American
aDisease activity in past 3 months was measured by using a patient self-reported 0–10 rating scale
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influential” and the weighted votes it was assigned in the
prioritization exercise. The results from the first NGT
meeting indicate that 4 of the 16 medication decision-
making facilitators were endorsed as being influential by
multiple patients and were assigned 34 (63 %) of the 54
available weighted votes (Fig. 1; see Additional file 1 for
more details). Presented relative to the “group-level” per-
ceived influence, the four facilitators generally concern
(1) the desire to be present or available for one’s children
(endorsed by 5 out of 9 patients; 24 % weighted votes),
(2) the will to live a longer life (endorsed by 5 out of 9 pa-
tients; 24 % weighted votes), (3) avoiding hospitalization
(endorsed by 2 out of 9 patients; 9 % weighted votes), and
(4) reducing the need for doctor visits (endorsed by 3 out
of 9 patients; 6 % weighted votes) (Fig. 1; see Additional
file 1 for more details).
The second NGT meeting was conducted at UAB with
seven African-American women patients who were on
average 49.1 (SD = 4.8 ; range, 42 to 56) years of age. Six
patients reported not having obtained a college degree,
and one patient reported that she had obtained a college
degree. During this meeting, patients generated 35 re-
sponses that reflected their thinking about medication
decision-making facilitators. Acting independently, pa-
tients in this group subsequently endorsed 14 of the 35
facilitators as having relatively more influence than the
facilitators that were not endorsed (Fig. 1b; see Additional
file 2 for more details). Based on multiple endorsements
and the assignment of weighted votes, patients in group 2
collectively perceived 6 of the 14 facilitators as having
had the greatest influence on their personal medication
decision-making processes. As a group, the six facilitators
were assigned 29 (69.1 %) of the 42 available weighted votes
(Fig. 1b; see Additional file 2 for more details). Patients in
this group were evenly divided with respect to what they
considered the most influential facilitator as indicated by
the similar endorsement profile associated with three differ-
ent facilitators. Specifically, two patients each endorsed and
assigned 14 % of the available votes to facilitators concern-
ing (1) having knowledge about medication side effects gen-
erally, (2) having knowledge about medication side effects
and how it affects other conditions or organs, and (3)
obtaining medication education as a way to avoid overlap
or duplication with other medication regiments. At least
two patients also endorsed the influence of facilitators con-
cerning (4) the desire to live a more normal life (endorsed
by 2 out of 7 patients; 12 % weighted votes), (5) medication
affordability (endorsed by 3 out of 7 patients, 7 % weighted
votes), and (6) assurance that the prescribed medication is
likely to help without causing other problems (endorsed by
2 out of 7 patients; 7 % weighted votes).
A third NGT meeting was conducted at UAB with an
additional seven African-American women who had a
mean age of 38.1 (SD = 11.9 ; range, 20 to 52) years. Four
of 7 patients reported that they have received a college de-
gree or above. This group generated 37 facilitators and se-
lected 13 facilitators as having more influence on their
own medication decision-making processes than the other
24 facilitators. Based on multiple endorsements and the
weighted votes criteria, patients in this meeting identified
six facilitators that accounted for almost 74 % of the
weighted votes (31 out of 42) available for prioritizing
facilitator influence (Fig. 1c; see Additional file 3 for more
details). The six facilitators concerned (1) affordability (en-
dorsed by 4 out of 7 patients; 14 % weighted votes), (2)
the potential of the medication to provide symptom relief
(endorsed by 2 of 7 patients, 14 % weighted votes), (3)
having knowledge of medication effectiveness (endorsed
by 2 out of 7 patients; 14 % weight votes), (4) assurance
that the medication is “approved” and not experimental
(endorsed by 2 out of 7 patients; 12 % weighted votes), (5)
having knowledge of side effects (endorsed by 2 out of 7
patients; 10 % weighted votes), and (6) understanding
what the benefits of the medication will be (2 out of
7 patient endorsements; 10 % weighted votes) (Fig. 1c;
see Additional file 3 for more details).
Table 2 Summary statistics for nominal group technique meetings (n = 52)




# of responses per
participant
# of prioritized responses
(R)




AA1 9 31 3.4 16 51.6 45.8
AA2 7 35 5.0 14 40.0 38.9
AA3 7 37 5.3 13 35.1 44.4
AA4 4 26 6.5 8 30.8 44.4
CA1 6 34 5.7 11 32.3 46.7
CA2 6 38 6.3 14 36.8 26.7
HA1 6 38 6.3 13 34.2 33.3
HA2 7 42 6.0 13 30.9 44.4
Total 52 281 5.4 102 36.3 35.3
AA African American, CA Caucasian American, HA Hispanic American
aRescaled agreement = (3 N − R)/ (3 N − 3) × 100, where N = number of participants, and R = number of prioritized responses
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A fourth NGT meeting at UAB involved four African-
American patients who had a mean age of 42.5 years
(SD = 14.9 ; range, 26 to 57 years). Two patients in this
group reported having obtained at least a college degree,
and two had not. The patients who participated in this
meeting generated a list of 26 responses representing
their views about medication decision-making facilita-
tors. From this list, they independently endorsed eight
facilitators as being relatively more influential in their
own medication decisions (Fig. 1d; see Additional file 4
for more details). Three facilitators were endorsed as in-
fluential by at least two patients. These accounted for
59 % of the available weighted votes and concerned (1) the
desire to live a normal life (endorsed by 2 out of 4 pa-
tients; 25 % weighted votes), (2) medication affordability
or low cost (endorsed by 3 out of 4 patients; 21 %
weighted votes), and (3) not having to worry about side ef-
fects (endorsed by 2 out of 4 patients; 13 % weighted
votes) (Fig. 1d; see Additional file 4 for more details).
A fifth NGT meeting involved six Caucasian women who
were patients at UAB. The patients in this group had a
mean age of 47.3 years (SD = 19.9 ; range, 21 to 72). One
of the patients reported having obtained a college degree,
and five patients reported having less education. As a
group, they generated a list of 34 facilitators and independ-
ently selected 11 facilitators from this list as having more
influence on their own medication decision-making than
other facilitators (Fig. 2a; see Additional file 5 for more de-
tails). Five facilitators were each endorsed as influential by
at least two patients and were assigned almost 67 % of the
Fig. 1 Prioritized facilitators to help patients make decisions about treatment choices in African-American patients in nominal groups 1 (a), 2 (b),
3 (c) and 4 (d). AA African- American, SES socioeconomic status, UAB University of Alabama at Birmingham
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0 5 10 15 20
My present health status and knowledge of my…
Not wanting to see organ shut down
Researching on my own
Desire to be with my family--my children
Seeing an improvement in overall health
Hoping that it will slow down the progression of…
Thinking that it will extend your life span
Desire to stay active/healthy
The desire to feel better
If the side effects are not significant
Because the doctors know more than I do
Weighted Votes (%)















0 5 10 15
If the drugs did not make you gain weight
Understanding the pros and cons of taking vs. not
taking drugs
If the doctor tell you what he wants and expects  to
see happen with you if you take the medication
Having a strong support systems (family encourage--
want you to get better)
Just knowing that your doctors are working together
for your treatment
Having a positive outlook on my diagnosis and
treatment
Knowing if taking the medication will  improve your
quality of life (QoL)
Doctor's knowledge of the drugs prescribed
Having proof of concept (evidence/statistics--that the
medication works)
If I knew if and when I would feel better
Having resources to pay for the drugs
Limited side effects
Understanding what am I taking
Having  good rapport with doctors and trusting them
Weighted Votes (%)
Fig. 2 Prioritized facilitators to help patients make decisions about treatment choices in Caucasian patients in nominal groups 1 (a) and 2 (b). CA,
Caucasian, SES socioeconomic status, UAB University of Alabama at Birmingham
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available weighted votes. The facilitators concerned (1) the
belief that their doctors were more knowledgeable than
they were themselves (3 out of 6 patient endorsements;
19 % weighted votes), (2) lack of significant medication side
effects (endorsed by 3 out of 6 patients; 14 % weighted
votes), (3) having the desire to feel better (endorsed by 2
out of 6 patients; 14 % weighted votes), (4) having the desire
to stay active (endorsed by 2 out of 6 patients; 11 %
weighted votes), and (5) belief that the medication will
increase longevity (endorsed by 2 out of 6 patient endorse-
ments; 8 % weighted votes) (Fig. 2a; see Additional file 5 for
more details).
The sixth and final NGT meeting conducted at UAB
involved six Caucasian women patients who had a mean
age of 45.7 years (SD = 11.5 ; range, 24 to 74). Four pa-
tients in this group indicated that they obtained at least
a college degree. Patients in this group generated 38 re-
sponses reflecting their views of potential medication
decision-making facilitators and subsequently endorsed
14 of these as relatively more influential than others
(Fig. 2b; see Additional file 6 for more details). At least
two patients from this group assigned one of their three
weighted votes to each of four facilitators, which
accounted for about 36 % of the weighted votes available
for prioritizing facilitator influence. These facilitators
were (1) having trust and rapport with physician (en-
dorsed by 2 out of 6 patients; 14 % weighted votes), (2)
having an understanding of medication (endorsed by 2
out of 6 patients; 8 % weighted votes), (3) limited side ef-
fects (endorsed by 2 out of 6 patients, 8 % weighted
votes), and (4) keeping a positive outlook about diagno-
sis and treatment (endorsed by 2 out of 6 patients; 6 %
weighted votes) (Fig. 2b; see Additional file 6 for more
details).
A seventh NGT meeting was conducted at UCSF with
a group of six Hispanic American women. The patients
in this group had a mean age of 31.7 years (SD = 12.2 ;
range, 19 to 51), and 5 out of 6 patients reported that
they did not have a college degree. This group generated
38 responses describing potential facilitators of medica-
tion decision-making. From this total, they selected 13
facilitators as being relatively more influential than
others in terms of their own medication decision-
making processes. At least two patients endorsed each
of four facilitators as influential and assigned almost
42 % of available weighted votes to them (Fig. 3a; see
Additional file 7 for more details). The four facilitators
concerned (1) motivation to return to a normal life (en-
dorsed by 3 out of 6 patients; 14 % weighted votes), (2)
receiving explanations of medication benefits and side
effects (endorsed by 2 of 6 patients; 11 % weighted
votes), (3) having assurance of results (cure) (endorsed
by 2 of 6 patients; 8 % weighted votes), and (4) to over-
come fatigue and weakness (endorsed by 2 of 6 patients;
8 % weighted votes). It should be noted that the six pa-
tients who participated in this meeting each endorsed a
different facilitator as most influential in their own
decision-making process (Fig. 3a; see Additional file 7
for more details).
The eighth and final NGT was also conducted at UCSF
and involved seven Hispanic American women who were
on average 35.4 years of age (SD = 12.0 ; range, 26 to 61).
Three patients reported having obtained a college degree.
This group generated 42 facilitators and subsequently se-
lected 13 as relatively more influential with respect to
their individual medication decision-making processes
(Fig. 3b; see Additional file 8 for more details). Six facilita-
tors were each endorsed as influential by at least two pa-
tients. Together, the six facilitators were assigned 69 % of
the weighted votes that were available for prioritizing per-
ceived influence. These facilitators reflected (1) the desire
to live (endorsed by 3 out of 7 patients; 21 % weighted
votes), (2) concern for their dependents (endorsed by 3
out of 7 patients; 14 % weighted votes), (3) flare-up pre-
vention (endorsed by 2 out of 7 patients; 12 % weighted
votes), (4) medication affordability (endorsed by 2 out of 7
patients; 9 % weighted votes), (5) having short-duration
treatment (endorsed by 2 out of 7 patients; 7 % weighted
votes), and (6) medication with a minimum of side effects
(endorsed by 2 out of 7 patients; 5 % weighted votes)
(Fig. 3b; see Additional file 8 for more details).
Discussion
This is the first detailed mixed methods study (qualitative
and quantitative) of facilitators of decision-making related
to medications for lupus nephritis. We purposefully over-
sampled African-American and Hispanic-American women
since the medication adherence is lower and outcomes are
worse compared with Caucasians with lupus [16, 17]. We
identified several key facilitators to medication decision-
making in our study, including effective patient-physician
communication regarding benefits/harms, patient desire to
live a normal life and concern for their dependents, experi-
encing benefits including improved quality of life and
symptom relief and few/infrequent/no harms with lupus
medications, and their affordability. Our study differs from
the previous work in this area in three major respects: (1)
we focused on facilitators to medication decision-making,
not adherence to lupus medication, an important but differ-
ent disease management construct; (2) we oversampled
racial/ethnic minorities to increase the generalizability of
study findings to the population of patients most severely
affected by lupus nephritis; and (3) we used NGT, which
allows both qualitative and quantitative assessment. In con-
junction with our recently completed work on barriers to
lupus nephritis medication decision-making [20], this new
knowledge is the first step in the development of an effect-
ive patient decision aid.
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0 5 10 15
Getting education about how the medicine would affect
my pregnancy
Having some education about the medications and
treatments
You've tried everything else and nothing  has worked
To stop joint pain
Knowing how to choose the night foods to take with
medicine
Worrying about the possible risk if the medicine is not
taken
To stop the swelling
To be able to have a healthy pregnancy in the future
To be able to live longer
To stop feeling weak and tired
If it gives good results-outcome or a cure
Getting an explanation of side effects and the benefits
the medicine has for my kidney
To be able to get back to your normal life
Weighted Votes (%)














0 5 10 15 20 25
Having some type of plan to get off of the
medicine
I don't want to get worse
I don't want to have dialysis again
Understanding how the medicine will affect my
ability to have children in the future
If the medicine had the least amount of side
effects
Knowing how long it will be before the medicine
takes effect?
Being informed about the specific side effects
that I can expect from taking the medication
Having some patient education about the
medication as opposed to the doctor saying…
Knowing how long the medicine has to be taken--
the shorter the better
Not costing more than I can afford
To prevent a flare-up
Thinking about the people who depend on me
Wanting to live
Weighted Votes (%)
Fig. 3 Prioritized facilitators to help patients make decisions about treatment choices in Hispanic patients in nominal groups 1 (a) and 2 (b). HA
Hispanic, SES socioeconomic status, UAB University of Alabama at Birmingham
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All groups identified the benefit of effective communi-
cation with their health-care provider as a key facilitator
to taking immunosuppressives regularly. Interestingly, in
some groups, there was more than one concept mapping
to this construct. This was an impressive finding since it
indicates that patients value communication very highly in
their decision to take or not to take lupus medications.
The key concepts/domains facilitating patient decision-
making related to lupus medications centered on the crit-
ical need to have better knowledge of the effectiveness of
the medications. Patients with lupus emphasized including
the following facilitators in effective patient-physician
communication: medication benefits, how their medica-
tion does or does not impact other conditions, the positive
impact of medication on their quality of life, how medica-
tion helps to slow down the progression of disease and al-
lows independence, avoids hospital admissions, and avoids
too many doctor visits and dialysis and how the medica-
tion leads to clear benefits to them. A recent systematic
review of qualitative studies identified effective communi-
cation, preserving health, negotiating medication regi-
mens, and financial burden among top themes for
medication adherence in patients with lupus [13]. How-
ever, most studies included in the systematic review did
not include racial minorities and focused on adherence ra-
ther than the decision to start lupus treatments including
immunosuppressive therapy. Our study examined these
facilitators in detail, included minority patients, and ex-
tended these findings to medication decision-making. Our
findings differ a bit from a UK study that included 13
black patients and reported that the facilitators of regular
intake of lupus medications were the belief that there was
no effective therapeutic alternative to their prescribed
medications and feelings of moral obligation or responsi-
bility to others and the fear of worsening disease [9]. We
found far more positive facilitators than reported in the
previous study. Differences in health-care systems (payer
versus socialized) and country setting (US versus UK)
might explain differences in findings.
A majority of the groups also identified that drug side
effects influenced their decision regarding lupus media-
tions. Important factors included not only a good know-
ledge and understanding of possible side effects but also
patient experience that side effects were minimal. Thus,
both the knowledge of potential side effects and a per-
sonal experience of few or no side effects with lupus
medications were important facilitators to decision-
making about lupus treatments. While it is intuitive to
think of fear of side effects as barriers to medication
decision-making in lupus and other chronic conditions,
our study shows that an adequate knowledge or experi-
ence (or both) can be a facilitator in this process.
Another important motivating factor for patients was
symptom relief they experienced with lupus medications.
This finding aligns with a similar finding in the system-
atic review that preserving health was a facilitator to
medication adherence in lupus [13] and extends it to
lupus medication decision-making. Similarly, medication
adherence in other chronic conditions is better with
medications that are associated with symptom relief [21]
or when the disease is symptomatic or both [22, 23].
However, this facilitator will apply only to patients
already taking other lupus medications or at the time of
retreatment with the same or similar medications.
Patients recognized the importance of lupus medica-
tions in prolonging life as well as improving their quality
of life and getting back to a normal way of living. As a
chronic autoimmune condition, lupus is associated with
significant morbidity and mortality in young patients in
their productive years. We found that the recognition of
illness severity and the reversal of disease impact on life by
lupus medications were perceived as facilitators and helped
patients make a decision favoring lupus medications.
Medication affordability was another facilitator for lupus
medication decision-making. In general, patients report
medication cost to be barrier to their use of medications.
Most medications for lupus are generic and usually are
covered by most insurance plans or provided as part of
patient assistance programs. We have included this mes-
sage regarding cost of medications in our lupus patient
decision aid, which is currently being tested in a random-
ized trial. In one of the nominal groups, one patient en-
dorsed “The fewer the medicine, the better” as a facilitator
for medication decision-making. This is not an uncom-
mon struggle many patients have with poly-pharmacy and
highlights the impact of poly-pharmacy on medication
decision-making and adherence. This topic is an import-
ant consideration for discussion at the time of giving a
new prescription to the patient, especially for organ-
saving medications used in the treatment of lupus.
In a previous study, patients with lupus identified a
lack of understanding of their disease, lack of under-
standing of psychosocial impact of lupus and their needs
by their lupus health-care experts, and lack of informa-
tion to address these needs [4]. Minority patients with
lupus (n = 29) identified the desire for lupus education,
need for assistance navigating the healthcare system, iso-
lation at the time of diagnosis, and the emotional and
physical barriers to care as the top targets; most (69 %)
favored a peer support intervention [3].
Some limitations must be considered while interpret-
ing these study findings. Since our NGTs were per-
formed in females, findings may not be generalizable to
men with lupus. It is possible that facilitators differ by
gender, and this should be explored in future studies.
Future studies should also consider whether lupus medi-
cation decision-making processes differ by the route of
medication administration (intravenous versus oral) and
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by the type of lupus medication (immunosuppressives
versus non-immunosuppressives versus biologics). Our
study does not address decision-making for other medi-
cations that patients with lupus take, such as anti-
hypertensives, lipid-lowering mediations, and cardiac
medications. Future research should address these im-
portant issues.
Conclusions
This mixed methods study used NGT to assess the facilita-
tors to the decision-making regarding medications for
lupus nephritis in African-American, Hispanic, and Cauca-
sian women with lupus. Several facilitators were identified
and prioritized by women with lupus. Considering our
study findings and previous research, we conclude that en-
gaging patients actively to acquire needed information to
facilitate medication decision-making is needed. Funded by
the Patient-Centered Outcomes Research Institute, we have
now developed a lupus decision aid based on the compre-
hensive knowledge of these facilitators as well as barriers to
medication decision-making [20]. A randomized trial to
assess whether this patient decision aid is effective in
improving patient medication decision-making regarding
lupus medications is under way. If found to be effective, this
decision aid will be available in the public domain for use
by lupus patients and their care providers. An effective
lupus patient guide and decision aid that provides balanced
scientific information about lupus medication from a pa-
tient perspective and in words patients can understand and
relate to can make it easier for patients to make informed
decisions about lupus medications.
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socioeconomic status, UAB University of Alabama at Birmingham
(DOCX 14 kb)
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Additional file 5: Prioritized facilitators in CA1 (n = 6) (UAB,
Birmingham, CA, 5 low SES, 1 high SES). This table provides a list of
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socioeconomic status, UAB University of Alabama at Birmingham (DOC 39 kb)
Additional file 6: Prioritized facilitators in CA2 (n = 6) (UAB,
Birmingham, CA, 2 low SES, 4 high SES). This table provides a list of
prioritized facilitators to help patients make decisions about treatment
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Birmingham (DOC 43 kb)
Additional file 7: Prioritized facilitators in HA1 (n = 6) (UCSF, San
Francisco, HA, 5 low SES, 1 high SES). This table provides a list of
prioritized facilitators to help patients make decisions about treatment
choices in Hispanic patients in nominal group 1. HA Hispanic American,
SES socioeconomic status, UCSF University of California at San Francisco
(DOC 39 kb)
Additional file 8: Prioritized facilitators in HA2 (n = 7) (UCSF, San
Francisco, HA, 4 low SES, 3 high SES). This table provides a list of
prioritized facilitators to help patients make decisions about treatment
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